Publications by authors named "Jingmei Xie"

Acute hepatopancreatic necrosis disease (AHPND) poses a significant threat to shrimp aquaculture worldwide, necessitating the accurate and rapid detection of the pathogens. However, the increasing number of species that cause the disease makes diagnosis and control more difficult. This study focuses on developing a monoclonal antibody against the insect-related (Pir) toxin B (PirB), a pivotal virulence factor in AHPND-causing , and establishing a colloidal gold immunochromatographic assay for the enhanced early diagnosis and monitoring of AHPND.

View Article and Find Full Text PDF

The pathogenic pVA1-type plasmids that carry toxin genes are the genetic basis for to cause acute hepatopancreatic necrosis disease (AHPND), a lethal shrimp disease posing an urgent threat to shrimp aquaculture. Emerging evidence also demonstrate the rapid spread of pVA1-type plasmids across species. The pVA1-type plasmids have been predicted to encode a self-encoded type IV secretion system (T4SS).

View Article and Find Full Text PDF

Endoscopic submucosal dissection (ESD) was commonly used for en bloc resection in gastric cancer and adenoma with the risk of delayed bleeding after ESD. We conducted a direct and indirect comparison meta-analysis to evaluate the best choice in preventing post-ESD bleeding among proton pump inhibitors (PPIs), histamine-receptor antagonists (HRAs), and the most widely used potassium-competitive acid blocker, vonoprazan. The Pubmed, Cochrane Library, and Embase were searched for randomized trials.

View Article and Find Full Text PDF

Many new regimens have been applied to newly diagnosed transplant-ineligible multiple myeloma, but no head-to-head research has been performed to compare the efficacy of these treatments. Currently lenalidomide plus dexamethasone (Rd) is one of the standard treatments. Our aim was to make a comparison of these treatments to Rd by a network meta-analysis.

View Article and Find Full Text PDF
Article Synopsis
  • Ixazomib is a proteasome inhibitor that targets the β5 subunit of the 20S proteasome, improving progression-free survival in multiple myeloma patients.
  • Approved by the FDA as an orphan drug in November 2015, it showed a median progression-free survival of 20.6 months when combined with lenalidomide and dexamethasone, compared to 14.7 months with placebo.
  • The drug has a generally favorable safety profile, with manageable low-grade side effects and ongoing trials assessing its effectiveness in various treatment settings.
View Article and Find Full Text PDF

Aims: This study aimed to investigate the efficacy and safety of dual therapy comprising sulfonylurea (SU) plus antidiabetic drugs for the treatment of type 2 diabetes mellitus (T2DM).

Methods: We searched the PubMed, Cochrane library, and Embase databases for randomized clinical trials (≥24 weeks) published up to December 28, 2017. Subsequently, we conducted pairwise and network meta-analyses to calculate the odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) of the outcomes.

View Article and Find Full Text PDF

We assessed the efficacy and safety of oral antidiabetic drugs (OADs) as an add-on treatment in patients with type 2 diabetes uncontrolled on metformin. PubMed, the Cochrane Library, and Embase were searched from inception to October 20, 2017. Pairwise and network meta-analyses were conducted using Stata 14.

View Article and Find Full Text PDF

Sensitization and activation of the trigeminal ganglia have been implicated in the pathology of migraine. Satellite glial cells (SGCs), a specialized type of glial cells that ensheathe trigeminal neurons, may be critical for peripheral nociceptive sensitization. Tetrandrine (TET), an alkaloid extracted from a traditional Chinese herb, exerts an inhibitory effect on glial activation in vitro and has been used in various neurologic diseases.

View Article and Find Full Text PDF

Protein kinase C γ (PKCγ) is a critical regulator of central sensitization and is widely recognized to be involved in the pathogenesis of chronic migraine (CM). However, the function of PKCγ in CM remains unknown. This study investigated the role of PKCγ on pathogenesis of CM.

View Article and Find Full Text PDF

Although two newly launched monoclonal antibodies (mAbs), elotuzumab and daratumumab, performed well in patients with relapsed or relapsed/refractory multiple myeloma (RRMM), their efficacy and safety remain uncertain. We therefore performed a systematic review and meta-analysis of the most recent clinical trials that evaluated elotuzumab and/or daratumumab for the treatment of patients with RRMM. Our meta-analysis included 13 clinical trials with 2,402 patients participating.

View Article and Find Full Text PDF

Tyrosine phosphorylation of NR2B (NR2B-pTyr), a subunit of the N-methyl-D-aspartate (NMDA) receptor, has been reported to develop central sensitization and persistent pain in the spine, but its effect in chronic migraines has not been examined. We hypothesized that tyrosine phosphorylation of NR2B contributes to chronic migraines (CM) through calcitonin gene-related peptide (CGRP) in rats. Ninety-four male Sprague-Dawley rats were subjected to seven inflammatory soup (IS) injections.

View Article and Find Full Text PDF

Objective: Activation of the trigeminal nucleus caudalis is believed to be involved in the pathomechanism of migraine. Evidence suggests that N-methyl-d-aspartate receptor subtype 2B tyrosine phosphorylation, originating from the trigeminal nucleus caudalis neuron dysfunction, might be a triggering mechanism for recurrent migraine. Phosphatase and tensin homolog is thought to have a neuroprotective effect in various neurologic diseases by regulating N-methyl-d-aspartate receptor subtype 2B or tyrosine phosphorylation.

View Article and Find Full Text PDF